Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » GVBP HUGE NEWS (Page 1)

 - UBBFriend: Email this page to someone!   This topic comprises 2 pages: 1  2   
Author Topic: GVBP HUGE NEWS
jdizz
Member


Member Rated:
4
Icon 1 posted      Profile for jdizz     Send New Private Message       Edit/Delete Post   Reply With Quote 
this company has a future imo

(OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), released important information about its innovative method for destroying breast cancer cells, using stem cell technology.

GENova's approach is based on cutting-edge technology that enables us to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures, says John Savin, VP for GENova. "By recognizing the existence of cancer stem cells, we have taken a great step towards understanding this complex disease. Now that we know how to identify the unique characteristics of these stem cells, we can develop cell-specific therapies that can eradicate them --and thus neutralize breast cancer right at the source."

The key behind GENova's biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose. Now that they are identifiable, scientists are developing tailor-made proteins that are programmed to destroy cancerous cells, whilst leaving the healthy cells intact. GENova has targeted these bio-engineered proteins for acquisition into its growing anti-cancer drug pipeline.

In the future, this technology will also enable us to identify healthy stem cells and then develop, inject, and nurture them in such a way that they can overcome the malignant cells. Eventually, healthy stem cells will overcome the sick cells, leaving the patient cured. This novel method for treating breast cancer is far superior to existing treatments, and is the underpinning of GENova's IP (Intellectual Property) portfolio.

Development of this important biotechnology would mean a new cure for cancer, rendering disfiguring mastectomies and harmful radiation therapies obsolete.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com

--------------------
dont make yourself loose money in a stock that you had a resonable profit in

Posts: 520 | From: houstonTX | Registered: Oct 2008  |  IP: Logged | Report this post to a Moderator
Charbel
Member


Member Rated:
5
Icon 1 posted      Profile for Charbel     Send New Private Message       Edit/Delete Post   Reply With Quote 
10 mil volume... seeming to have difficulty passing .259
Posts: 276 | From: Wichita, KS | Registered: Aug 2009  |  IP: Logged | Report this post to a Moderator
Charbel
Member


Member Rated:
5
Icon 1 posted      Profile for Charbel     Send New Private Message       Edit/Delete Post   Reply With Quote 
here we go [Smile]
Posts: 276 | From: Wichita, KS | Registered: Aug 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
Sorry... I did not see this thread before I posted same symbol. Continue with this one. thanks.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
New stem cell identification technology could cure breast cancer

Sep 11, 2009 06:00:00 (ET)


NEW YORK, Sept 11, 2009 /PRNewswire-FirstCall via COMTEX/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), released important information about its innovative method for destroying breast cancer cells, using stem cell technology.

GENova's approach is based on cutting-edge technology that enables us to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures, says John Savin, VP for GENova. "By recognizing the existence of cancer stem cells, we have taken a great step towards understanding this complex disease. Now that we know how to identify the unique characteristics of these stem cells, we can develop cell-specific therapies that can eradicate them --and thus neutralize breast cancer right at the source."

The key behind GENova's biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose. Now that they are identifiable, scientists are developing tailor-made proteins that are programmed to destroy cancerous cells, whilst leaving the healthy cells intact. GENova has targeted these bio-engineered proteins for acquisition into its growing anti-cancer drug pipeline.

In the future, this technology will also enable us to identify healthy stem cells and then develop, inject, and nurture them in such a way that they can overcome the malignant cells. Eventually, healthy stem cells will overcome the sick cells, leaving the patient cured. This novel method for treating breast cancer is far superior to existing treatments, and is the underpinning of GENova's IP (Intellectual Property) portfolio.

Development of this important biotechnology would mean a new cure for cancer, rendering disfiguring mastectomies and harmful radiation therapies obsolete.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
jdizz
Member


Member Rated:
4
Icon 1 posted      Profile for jdizz     Send New Private Message       Edit/Delete Post   Reply With Quote 
UP 35% doing well

--------------------
dont make yourself loose money in a stock that you had a resonable profit in

Posts: 520 | From: houstonTX | Registered: Oct 2008  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
I think it will even go higher before the day is over. The news is great news !!
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
It's now up 44.36%
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
jdizz
Member


Member Rated:
4
Icon 1 posted      Profile for jdizz     Send New Private Message       Edit/Delete Post   Reply With Quote 
i wish i got into it when i posted it.. they did a foward split in april 2009..i dunno how to take that.. i want to research this company, maybe it has a good future?

--------------------
dont make yourself loose money in a stock that you had a resonable profit in

Posts: 520 | From: houstonTX | Registered: Oct 2008  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
It,s now up 46.74%....great job !
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
The below is what I read about the company :

GVBP is positioning themselves to be the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers.

One in four deaths in the United States is due to cancer. It's a disease that puts us in great fear. It can attack viciously and quickly.

Cancer treatments today are based on highly toxic chemotherapy with significant side-effects.

However, new developments are emerging. These are based on targeted therapies directed specifically at the cancer, without harming healthy cells.

GVBP's mission is to create a new generation of targeted human therapeutics – safe medicine that works against a variety of cancers and infectious diseases. The company is dedicating all of their efforts in the development and commercial licensure of novel therapeutic proteins disrupting the growth of cancers.

A prostate cancer target and a breast cancer target are included in GVBP's patented drug and product portfolio, as well as a promising acquisition pipeline.

Among GVBP's proprietary and most promising anti-cancer candidates include Tetanolic acid, which targets breast cancer and Prostaganin, a peptide for=2 0prostate cancer.

In the United States, more than 2.8 million women are living with breast cancer, one million of whom have yet to be diagnosed.

That's scary to even imagine. One million women are walking around with breast cancer and don't even know it yet!

It is the most common cancer and the most common cause of cancer death among women worldwide.

Known as an alpha hydroxyoleic acid, Tetanolic acid targets breast cancer. It is a form of a lipid which is also found as a main component of olive oil. Alpha hydroxyoleic acids are able to interact with the cell membrane in order to control its composition or structure with affect on the receptors on the membrane.

This control mechanism affects the growth and proliferation of cells – and seeing that cancer is characterized as a normal proliferation of cells, these lipids can potentially prevent cancer spread.

GVBP could one day dominate the therapeutics market for breast cancer with an anti-cancer candidate like this!

This is a market that is expected to grow to $11.5 billion by 2011!

The market for prostate cancer therapies is no joke either amounting to $1.5 billion (Drugresearcher.com).

Prostate cancer is the second leading casue of death in North American men.

GVBP's Prostaganin is a peptide for prostate cancer and is a candidate for development of an anti-cancer medicament for treatment of humans.

For humans, one of the peptides’ most important qualiti es is the ability to demonstrate complete inhibition of growth of prostate tumour xenografts. Furthermore, they can markedly reduce the secretion of the prostate-specific antigen (PSA), a biomarker widely known to be indicative of this malignancy.

GVBP is evaluating up to four additional product candidates for acquisition. These biological products candidates are directly targeted at the treatment of cancer and infectious disease indications representing substantial unmet needs and significant blockbuster potential.

The future for GVBP is promising as even President Obama has proposed to increase cancer research funding to $6 billion!!

GVBP leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec!

GVBP has all the components to one day becoming a biotech giant. Make sure you do all your research. Biotechs in general can by very risky so make sure to do your research pefectly well. If you like you may consult with a financial professional before you invest.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova issues clarifying press release

Sep 12, 2009 15:17:00 (ET)


NEW YORK, Sept 12, 2009 /PRNewswire-FirstCall via COMTEX/ -- GENova Biotherapeutics Inc. ("GENova") clarified today information disseminated in previous press releases regarding the patents currently in GENova's IP portfolio.

GENova owns the rights to a range of drug targets and has filed patent application for all of them. The patents have not yet been approved and are therefore considered 'patents-pending'. It has been brought to GENova's attention that previous releases were not entirely clear on this issue and may have been misconstrued by some investors. Any statements made prior to this announcement which stated or implied that patents have been granted are incorrect and should not be relied upon in making investment decisions.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies.Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova appoints Dr. Philip Gould to Scientific Advisory Board

Sep 13, 2009 13:12:00 (ET)


NEW YORK, NY, Sept 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Philip Gould as a Member Designate of its Scientific Advisory Board (SAB, Trade ).

Dr. Gould will contribute his career experience in multinational blue chip drug discovery companies as well as his drug patenting experience to GENova's business of identifying, evaluating and developing pioneering research drugs

Aaron Whiteman, CEO of GENova, says, "Mr. Gould's esteemed position as an international business leader in the healthcare and drug development sectors is an asset to GENova."

About Dr. Philip Gould

Mr. Gould is presently the Chief Business Officer of the Liverpool School of Tropical Medicine, the first institution of its kind dedicated to research in tropical medicine. He also maintains his position as Founder and CEO of Jadara Pharma Ltd, a profitable healthcare business consultancy with contracts in strategic business planning, fund raising, patent litigation, strategic product development, spin out portfolio management and investor support to trade sale or IPO. Previously, he was CEO of Provalis plc, a pharmaceutical and medical diagnostics company. Other positions have included Principle Research Scientist and Senior Manager of Pharmaceutical Development for Pfizer, and Head of New Product Development for GlaxoSmithKline.

He has produced over 20 publications as a primary author, and has presented 25 papers at seminars on a variety of both technical and managerial subjects, and has been named as an inventor on 4 patents. He holds a Ph.D in Physical Chemistry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer (PFE, Trade ), Amgen (AMGN, Trade ), Myriad Genetics (MYGN, Trade ), Medarex (Nasdaq: MEDX), and Biogen Idec (BIIB, Trade ) . Visit GENova online at www.genovabio.com

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
jdizz
Member


Member Rated:
4
Icon 1 posted      Profile for jdizz     Send New Private Message       Edit/Delete Post   Reply With Quote 
if your in this watch out though b.c i know its being pumped by a stock newsletter. alot of talk about this being a scam. who knows if it is or not, jsut watch out

--------------------
dont make yourself loose money in a stock that you had a resonable profit in

Posts: 520 | From: houstonTX | Registered: Oct 2008  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova Biotherapeutics prepares a 510(k) submission to the FDA

Sep 14, 2009 07:00:00 (ET)


NEW YORK, Sept 14, 2009 /PRNewswire-FirstCall via COMTEX/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration ( www.fda.gov ) for a 510(K, Trade ) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

Prostaganin: Peptide for prostate cancer

For humans, one of the peptides' most important qualities is the ability to demonstrate complete inhibition of growth of prostate tumour xenografts. Furthermore, they can markedly reduce the secretion of the prostate-specific antigen (PSA), a biomarker widely known to be indicative of this malignancy. Therefore, GENova's Prostaganin is a candidate for development of an anti-cancer medicament for treatment of humans.

Representing the most commonly diagnosed non-cutaneous cancer in ageing males, prostate cancer is the second leading cause of death in North American men. At present, the anti-androgen and LHRH analog drug classes dominate the market. However, with the development of a number of innovative therapies entering the market for the first time, the prostate cancer market will enter a more dynamic and high growth phase. By now, the market for prostate cancer therapies amounts to US$1.5 billion (Drugresearcher.com). But as newer and more innovative therapies are applied, the market is set to experience double digit growth and GENova wants to participate in this rapidly growing market.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
jdizz
Member


Member Rated:
4
Icon 1 posted      Profile for jdizz     Send New Private Message       Edit/Delete Post   Reply With Quote 
dang up 40% again..

--------------------
dont make yourself loose money in a stock that you had a resonable profit in

Posts: 520 | From: houstonTX | Registered: Oct 2008  |  IP: Logged | Report this post to a Moderator
Dagny
Member


Rate Member
Icon 1 posted      Profile for Dagny     Send New Private Message       Edit/Delete Post   Reply With Quote 
I believe it is a scam, but I made some cash on it. It used to be a travel agency that went defunk. Kinder travel or something like that. They have no financing and no money. From my e-mail... StockRich.com has been compensated by a third party one hundred forty five thousand dollars for a one week GVBP advertising services contract. StockRich.com has been previously compensated by a third party one hundred twenty five thousand dollars for a one week GVBP advertising services contract which has expired.
So, it may go up like a rocket, but be very careful from this point on

--------------------
Dagny

Posts: 271 | From: Arkansas | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova appoints Dr. Wang Chong to Scientific Advisory BoardFont size: A | A | A10:00 PM ET 9/14/09 | PR Newswire
(OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Wang Chong to its Scientific Advisory Board.

Dr. Wang Chong will contribute his considerable expertise to the company as it pursues its mandate to develop, patent and commercialize ground-breaking cancer-fighting biotechnologies, with a focus on breast and prostate cancer.

Aaron Whiteman, CEO of GENova stated, "GENova is proud to have attracted such an esteemed me member of the healthcare industry to assist us in our growth plans."

About Dr. Wang Chong

Dr. Wang Chong is a physician with over 19 years of experience in the healthcare industry, whose expertise lies in raising capital for and listing small to medium-sized companies. Previous positions include CFO and Commercial Director of Phytopharm plc, CEO of Osmetech plc, Life Sciences Analyst at Canaccord Capital (Europe) Ltd, Leader of UK Healthcare Initiatives at premier management consultants Arthur D. Little Inc, and commercial roles at Glaxo Wellcome plc and SmithKline Beecham plc. Chong graduated with a medical degree from King's College London and a MBA from London Business School. He is also a Council Member of the Royal Society of Medicine's Pharmaceutical Medicine Research Section and an Associate of the Securities and Investment Institute.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova Biotherapeutics signs collaboration agreement with Bridge BioresearchFont size: A | A | A4:30 PM ET 9/14/09 | PR Newswire
RELATED QUOTES


3:59 PM ET 9/14/09
Symbol Last % Chg
GVBP 0.43 48.28%
Real time quote.

(OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced it has signed a collaboration agreement with Bridge Bioresearch Plc. ("Bridge Bioresearch"), an international drug development and discovery company that focuses on metabolic disorders.

The two biotechnology drug acquisition companies plan to leverage each others' scientific findings and industry contacts for mutual gain.

GENova's business solely focuses on cancer cures, while Bridge BioResearch is geared at acquiring drug targets for Obesity and Type 2 Diabetes. Through the collaboration agreement, the two companies will partner to share research results and their global contacts with research organizations and pharmaceutical companies. They will also examine their findings to gain insight into the links between their respective fields of oncology and obesity, as cancer and obesity are both maladies that can be blamed on lifestyle choices.

"By collaborating with Bridge BioResearch, we will gain access to their excellent network of high quality research labs and universities around the world, as well as their well-established distribution channels," says Aaron Whiteman, CEO for GENova. "We are confident that through this collaboration, we will gain access to the latest and greatest in developmental cancer drugs to perpetuate our acquisition pipeline, as well as secure reliable distribution channels for our out-licensing objectives."

"Furthermore, through this collaboration, we will exchange our scientific findings to gain insight into the links between obesity and cancer, as many findings suggest that one of the main factors in cancer development is lifestyle choices, including unhealthy diet," says Whiteman.

About Bridge Bioresearch

Bridge BioResearch is a drug discovery company with the sole corporate focus on Obesity, Type 2 Diabetes and related metabolic disorders. It has research cooperation agreements with leading Research and Development Services providers and bioscience research institutions and universities throughout Asia and Europe. The company uses a cost-efficient technology and patent acquisition strategy for proprietary intellectual property from identified companies, government institutions and universities, paid via milestone-dependent research collaborations and grants. To learn more about Bridge BioResearch, visit www.bridgebioresearch.com.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
western acres
Member


Rate Member
Icon 1 posted      Profile for western acres     Send New Private Message       Edit/Delete Post   Reply With Quote 
Origenal post:
I believe it is a scam, but I made some cash on it. It used to be a travel agency that went defunk. Kinder travel or something like that. They have no financing and no money. From my e-mail... StockRich.com has been compensated by a third party one hundred forty five thousand dollars for a one week GVBP advertising services contract. StockRich.com has been previously compensated by a third party one hundred twenty five thousand dollars for a one week GVBP advertising services contract which has expired.
So, it may go up like a rocket, but be very careful from this point on

--------------------
Dagny

Dagny, do you still feel this is a scam or is it because of the specific pr company involved. How can you tell if the people coming on board are not really joining the co.? Or if the company
above is only in talks and not likely to actually join?
Thanks, W-A

Choose your Heroes wisely.

Posts: 49 | From: Texas | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
Skymark Research Initiates Independent Research Coverage On Genova Biotherapeutics, Inc.

Sep 15, 2009 09:25:54 (ET)


CALGARY, Alberta, Sep 15, 2009 (GlobeNewswire via COMTEX) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Genova Biotherapeutics, Inc. (GVBP, Trade ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com

About SMR:

Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php .

About Genova Biotherapeutics, Inc. (GVBP, Trade ):

Genova Biotherapeutics, Inc (GVBP, Trade ) is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit Genova online at www.genovabio.com .

SMR Disclosure:

Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com , for complete risks and disclosures.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Skymark Research


CONTACT: Skymark Research
Dylan Boyle
202-657-6249
info*skymarkresearch.com

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
jdizz
Member


Member Rated:
4
Icon 1 posted      Profile for jdizz     Send New Private Message       Edit/Delete Post   Reply With Quote 
since i posted it on monday it has went up double its price

--------------------
dont make yourself loose money in a stock that you had a resonable profit in

Posts: 520 | From: houstonTX | Registered: Oct 2008  |  IP: Logged | Report this post to a Moderator
Dagny
Member


Rate Member
Icon 1 posted      Profile for Dagny     Send New Private Message       Edit/Delete Post   Reply With Quote 
To Western Acres: The reason I think it may be a scam is from their 10-Q report filed 10/14/09. As stated before it used to be Kinder Travel KNDT:OB.
The company was going broke, and now it changes the name and has the cure for cancer??I just find this a little hard to believe. I may be wrong, just research and be careful.

--------------------
Dagny

Posts: 271 | From: Arkansas | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
Related Quotes
Sym. Price Chg.
GVBP Trade
News 0.795 0.365
GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure

Sep 15, 2009 11:30:00 (ET)


NEW YORK, NY, Sept 15, 2009 /PRNewswire-FirstCall via COMTEX/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced it has signed an LOI with Prime BioResearch, Ltd. ("Prime BioResearch"), another drug acquisition company in the areas of drug development and distribution a business case that will save GENova millions every year in drug development and at the same time more than double GENova's distribution network enabling GENova to potentially exceed its own expectations of reaching 100m+ in revenue in year 3

GENova and Prime BioResearch will collaborate to share best practices, scientific expertise and to leverage their mutual networks of global bioscience Research and Development organizations and drug distribution channels.

The two companies are both in the business of acquiring early-stage developmental drugs, and out-licensing them for development and commercialization, and garnering royalty payments in the process. GENova's focus is oncology, while Prime BioResearch specializes in Obesity, Type 2 Diabetes and other metabolic disorders.

"While Prime BioResearch aims to cure metabolic disorders, and GENova seeks cancer cures, our two companies have much in common, and we can learn a lot from each other and help each other towards success," says Aaron Whiteman, CEO for GENova.

Both companies share a mutual goal of fast-tracking their target drugs through development, clinical studies, licensing to Large Pharma Companies, and finally to market. Navigating the myriad of channels to do so can be complex, and so by sharing strategies in efficiency, both GENova and Prime BioResearch will mutually benefit. The ultimate goal is to get their promising anti-cancer and anti-obesity drugs to market as soon as possible.

About Prime BioResearch

Prime BioResearch Ltd. is in the business of identifying, evaluating and acquiring potential blockbuster developmental drugs in medical markets with significant growth potential. Prime BioResearch currently has a proprietary portfolio of six worldwide patents in Obesity and Diabetes-II worth $2.9 billion, if successfully brought through development, clinical trials, and to market (Source: PriceWaterhouseCoopers). The Company's mission is to make safe and effective drugs available to the public, quickly and at affordable levels.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: www.genovabio.com

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
jdizz
Member


Member Rated:
4
Icon 1 posted      Profile for jdizz     Send New Private Message       Edit/Delete Post   Reply With Quote 
man i wish i could have gotten in this... 80% today!

--------------------
dont make yourself loose money in a stock that you had a resonable profit in

Posts: 520 | From: houstonTX | Registered: Oct 2008  |  IP: Logged | Report this post to a Moderator
trade4pepper
Member


Rate Member
Icon 1 posted      Profile for trade4pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
quote:
Originally posted by Dagny:
To Western Acres: The reason I think it may be a scam is from their 10-Q report filed 10/14/09. As stated before it used to be Kinder Travel KNDT:OB.
The company was going broke, and now it changes the name and has the cure for cancer??I just find this a little hard to believe. I may be wrong, just research and be careful.

I agree. I did not jump in because of the same thought process. How does a company go from travel to curing cancer?

Better safe than sorry.

Posts: 44 | From: Florida | Registered: May 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GVBP has hit $1.12 and it's rising.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova and TheraGlass in advanced negotiationsFont size: A | A | A6:00 AM ET 9/16/09 | PR Newswire
(OTCBB: GVBP.OB.) - GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.

TheraGlass, classified as a medical device, interacts with the body's tissues to stimulate cell growth and provide vital anti-bacterial, structural, and regenerative proteins. It is entirely non-toxic and is reabsorbed and excreted through the body's natural metabolic processes.

The two companies are already actively exploring the possibilities and opportunities of combining TheraGlass IP with GENova's drug targets; which will create a brand new class of blockbuster therapeutic drugs for the treatment of cancer. This advancement is potentially worth significant amounts in royalty payments should GENova be successful in creating this new class of drug treatment.

The two companies have entered into an LOI for GENova to acquire a number of TheraGlass Ltd's patents, the deal is expected to close in Q4 and will see GENova significantly increase its overall value of its IP portfolio and thereby move closer to position itself as a possible takeover target for a major pharmaceutical company.

"The potential for augmenting cancer treatments with a regenerative product like TheraGlass is tremendous," says GENova CEO Aaron Whiteman. "While GENova's treatments destroy cancerous cells, TheraGlass can stimulate healthy cells to regenerate, thus expediting the healing process."

The two companies are mapping out the deal and plan on making the details of that deal public in the coming weeks.

About TheraGlass Ltd.

TheraGlass Ltd. has an exclusive international position for the commercialisation of sol-gel derived bioactive glass under the trade name TheraGlass. Discovered by Professor Larry Hench and developed at Imperial College London, TheraGlass is the next generation of bioactive glass, a medical device material that can interact with the body's hard and soft tissues to stimulate cell growth, accelerating the body's self healing properties. TheraGlass has potential uses in diverse fields including as a replacement for autologous (i.e. self donor) bone grafts, 3D craniofacial reconstruction, the replacement of collagen sponges, as a tissue engineering scaffold (seeded with stem cells), in wound treatments from battlefield dressings and bedsore to domestic first aid kits, in drug delivery, dental fillers, toothpaste to heal sensitive teeth, and even cosmetic applications.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
western acres
Member


Rate Member
Icon 1 posted      Profile for western acres     Send New Private Message       Edit/Delete Post   Reply With Quote 
So here is the real question. Where do we git out? I read an article about this being a good pump job. Anatomy of a Pump & Dump on the Motley Fool.
http://caps.fool.com/****s/ViewPost.aspx?bpid=260030&t=01001529370998141183

I really appreciate the advice.
W-A

Posts: 49 | From: Texas | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
Now it's at 1.18 and will take a short drop before picking up again.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
buckstalker
Member


Member Rated:
4
Icon 1 posted      Profile for buckstalker     Send New Private Message       Edit/Delete Post   Reply With Quote 
And...there's the DUMP

--------------------
***********************

It's all in the timing...

Posts: 4303 | From: DSA | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
THE DUKE
Member


Rate Member
Icon 1 posted      Profile for THE DUKE         Edit/Delete Post   Reply With Quote 
GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
Last update: 9/16/2009 11:00:00 AM
NEW YORK, NY, Sept 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed an engagement agreement with PacificWave Partners Limited ("PacWave") for raising a minimum of USD5m to the company as well as actively look for potential buy-out and/or acquisition targets.
The deal will entail an upcoming visit to the US where the management team will be meeting hedge funds and institutional investors, PacWave is confident that with the strength of the management team as well as the liquidity in the company's stock that financing can be secured within a timely fashion and under very favorable terms.
In addition to the fund raising effort, PacWave will approach a number of major pharma companies which are currently active making acquisitions of smaller biotech companies and position GENova as a potential next acquisition target.
About PacificWave Partners Limited
PacificWave Partners is a privately held international financial advisory firm providing investment banking services to privately-held and publicly-traded micro, small and mid capitalization companies throughout Asia, Europe and North America. PacificWave is headquartered in Copenhagen, Denmark with offices in San Francisco, Los Angeles and New York and specializes in capital raises between USD5m - USD50m
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec.
Forward Looking Statements

Posts: 251 | From: nashville | Registered: Jan 2007  |  IP: Logged | Report this post to a Moderator
Burberry Boy
Member


Member Rated:
4
Icon 1 posted      Profile for Burberry Boy     Send New Private Message       Edit/Delete Post   Reply With Quote 
put a .55 buy when it was at .50 on ask and it finally filled like 5 min later at .549...this is going to run hard !
Posts: 1264 | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
beerlady
Member


Member Rated:
4
Icon 1 posted      Profile for beerlady     Send New Private Message       Edit/Delete Post   Reply With Quote 
omg, dizz, see what I was saying?
Posts: 254 | From: Middle of Kansas | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
  This topic comprises 2 pages: 1  2   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2019 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share